<DOC>
	<DOC>NCT01795716</DOC>
	<brief_summary>1. purpose: To conduct the relative bioavailability study of a single dose and multiple doses of imatinib mesylate capsule (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus Glivec (Novartis Pharma Stein AG). 2. Experimental Design： Two-period crossover design 3. Test drug: imatinib mesylate capsule Reference drug: Glivec 4. Sample size：20</brief_summary>
	<brief_title>Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body</brief_title>
	<detailed_description>To conduct the relative bioavailability study of a single dose and multiple doses of imatinib mesylate capsule(Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus Glivec (Novartis Pharma Stein AG) and compare the bioequivalence and pharmacokinetics of the two products in 20 patients with chronic myeloid leukemia.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients with chronic myeloid leukemia; Age: 1865 years,gender:both. Weight: standard weight ± 20% within, and avoid weight disparity is too large; No previous radiation therapy, chemotherapy, or surgery within 1 weeks before treatment with imatinib; Performance status 0 to 3 (WHO scale); Life expectancy greater than 3 months; No other malignancy; Adequate hepatic, renal, and bone marrow function (WBC≥3.0×109/L，ANC≥1.5×109/L，PLT≥80×109/L. Serum bilirubin≤1.5×the institutional upper limit of normal, ALT、ALP≤2.5×the institutional upper limit of normal, creatinine≤1.5×the institutional upper limit of normal); Ability to understand objectives of the study, the study procedure, the pharmacological properties of the drug and possible adverse reactions and the willingness to sign a written informed consent. Suffering from heart, liver, kidney disease or severe acute and chronic gastrointestinal diseases; Pregnant or lactating women and be sensitive to drug; Subjects are thought unsuitable for the study by investigators; Inability to comply with protocol or study procedures in the opinion of the investigator; Attending other clinical trials or attended other clinical trials 3 months ago.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>